Related Experiment Video
Updated: May 1, 2026
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
9.0K
Intestinal Probiotic Lysate Modified Bifunctional Nanoparticle for Efficient Colon Cancer Immunotherapy
Manfang Zhu1, Hongkui Chen2, Xiaohua Chen3
1Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Pharmaceutics
|February 26, 2025
Summary
This study developed a novel gene delivery system using probiotic lysate to enhance cancer immunotherapy. The system efficiently delivers siRNA, activates immune cells, and suppresses colon cancer growth with high safety.
Area of Science:
- Oncology
- Immunology
- Gene Therapy
- Nanotechnology
Background:
- Cancer immunotherapy utilizes gene therapy, but efficient non-viral delivery systems with immune activation are needed.
- Intestinal probiotics like *Lactobacillus reuteri* show potential in cancer progression and possess immunomodulatory properties.
- Developing advanced gene delivery platforms is crucial for effective cancer treatment strategies.
Purpose of the Study:
- To engineer a novel non-viral siRNA delivery system (DMPLAC) using *Lactobacillus reuteri* lysate.
- To evaluate the system's efficiency in siRNA delivery and immune cell activation.
- To assess the therapeutic potential of DMPLAC/siCD47 complexes in colon cancer models.
Main Methods:
- Engineered DMPLAC nanoparticles by encapsulating *Lactobacillus reuteri* lysate.
- Assessed siRNA delivery efficiency in vitro and immune cell activation (dendritic and T cells) in vitro and in vivo.
- Administered DMPLAC/siCD47 complexes targeting the CD47 gene locally in colon cancer models.
Main Results:
- DMPLAC nanoparticles demonstrated high in vitro siRNA delivery efficiency (up to 97.62%).
- Significant promotion of dendritic and T cell maturation and activation was observed both in vitro and in vivo.
- DMPLAC/siCD47 complexes effectively suppressed colon cancer growth with a favorable safety profile.
Conclusions:
- A novel gene delivery system based on intestinal probiotic lysate was developed.
- The system exhibits dual immunomodulatory abilities, enhancing anti-cancer immune responses.
- This probiotic-derived platform offers a promising strategy for advanced cancer immunotherapy.
